1. Stocks
    2. /
  2. Neuren Pharmaceuticals Limited (ASX: NEU)
    3. /

Neuren Pharmaceuticals Limited (ASX: NEU) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Neuren Pharmaceuticals Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

    • Neuren Pharmaceuticals Limited (ASX: NEU)
    Latest News

    A panel of four judges hold up cards all showing the perfect score of ten out of ten
    Share Market News

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    Investors seemed buoyed by the latest inflation figures today...

    Read more »

    View of a business man's hand passing a $100 note to another with a bank in the background.
    Growth Shares

    Invest $10,000 into these ASX 200 shares in January

    | James Mickleboro

    Market-beating returns could be on offer from these shares this year according to analysts.

    Read more »

    happy investor, share price rise, increase, up
    Growth Shares

    3 fantastic ASX 200 growth shares to buy in 2025

    | James Mickleboro

    Analysts have good things to say about these buy-rated shares.

    Read more »

    Hand holding Australian dollar (AUD) bills, symbolising ex dividend day. Passive income.
    Growth Shares

    Invest $5,000 into these ASX 200 shares in 2025

    | James Mickleboro

    Analysts think these shares could be top options for an investment in 2025.

    Read more »

    A man sits on a bench atop a mountain with a laptop, making investments with a green ESG mind.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    Investors endured another rough trot this hump day.

    Read more »

    Hands reaching high for a trophy with a sunset in the background.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was another day and another record high for ASX shares.

    Read more »

    A smiling travel agent sitting at her desk working for Corporate Travel Management
    Growth Shares

    My 2 best ASX growth shares to buy in November

    | Zach Bristow

    Growth continues to catch the market's attention.

    Read more »

    A man sees some good news on his phone and gives a little cheer.
    Growth Shares

    These ASX 200 growth shares could rise 50% to 60%

    | James Mickleboro

    Big returns could be on offer from these growing companies according to analysts.

    Read more »

    asx share price boosted by us investment represented by hand waving US flag across winning athlete
    Best Shares

    Here are the best-performing ASX 200 shares since the US election result

    | Bronwyn Allen

    We reveal the 10 ASX stocks that have had the highest share price gains since the US Presidential election.

    Read more »

    A golfer celebrates a good shot at the tee, indicating success.
    Share Market News

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    ASX investors finally enjoyed a win this Thursday...

    Read more »

    drug capsule opening up to reveal dollar signs signifying rising asx share price
    Healthcare Shares

    3 ASX healthcare shares going gangbusters on Thursday

    | Bernd Struben

    Investors are sending these ASX healthcare stocks soaring today. But why?

    Read more »

    Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    ASX investors endured another day of selling this Tuesday.

    Read more »

    Frequently Asked Questions

    No, Neuren Pharmaceuticals does not pay dividends at this time. 

    Neuren Pharmaceuticals Limited (ASX: NEU) listed on the ASX on 3 February 2005.

    NEU ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Neuren Pharmaceuticals Limited

    Neuren Pharmaceuticals Limited (ASX: NEU) is a biopharmaceutical company specialising in developing new therapies for neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells. 

    In March 2023, the US Food and Drug Administration approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adults and children two years and older. Neuren's US partner Acadia Pharmaceuticals (NASDAQ: ACAD) holds a worldwide exclusive licence from Neuren for trofinetide. At this time, DAYBUE is the first and only drug approved for the treatment of Rett syndrome. Trofinetide has also demonstrated clinical benefit in a Phase 2 trial in treating Fragile X syndrome.

    Neuren's second product NNZ-2591 is currently in Phase 2 clinical trials for the treatment of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome. The drug candidate has shown positive effects in mouse models of each syndrome and was successful in a Phase 1 clinical trial. The number of patients across these four disorders is estimated as five times the number of Rett syndrome patients. There are currently no drugs approved for these conditions, apart from growth hormone to treat some aspects of Prader-Willi. 

    Acadia Pharmaceuticals also holds a worldwide exclusive licence to develop and commercialise NNZ-2591 for Rett syndrome and Fragile X syndrome. Neuren retains worldwide rights to NNZ-2591 in all other indications.

    Profile

    since

    Note